Date | Title | Description | |
---|---|---|---|
10 May 2023 | On P&L | The Company releases the press release related to the first quarter 2023 financial results | Download |
25 Apr 2023 | On business and financial situation | ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) | Download |
21 Feb 2023 | On business and financial situation | The Company releases the full year 2022 financial results presentation. | Download |
21 Feb 2023 | On business and financial situation | The Company releases the press release related to the full year 2022 financial results. | Download |
21 Feb 2023 | On business and financial situation | The company releases the Integrated Report for the year 2022 | Download |
Pages
Date | Title | Description | |
---|---|---|---|
10 Apr 2023 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the first quarter of 2023 | Download |
21 Feb 2023 | Annual Corporate Governance Report | ROVI releases the 2022 Annual Corporate Governance Report | Download |
21 Feb 2023 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2022 annual report regarding remuneration of the members of the Board of Directors | Download |
16 Feb 2023 | On business and financial situation | The Company informs on the evaluation process to obtain marketing authorisation for Risvan® (Risperidone ISM®) in the United States. | Download |
09 Jan 2023 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the fourth quarter of 2022 | Download |
Pages
Date | Title | Description | |
---|---|---|---|
21 Feb 2012 | Información sobre resultados (2) | Download | |
21 Feb 2012 | Información sobre resultados | Download | |
21 Feb 2012 | Informe Anual de Gobierno Corporativo | Download | |
15 Feb 2012 | Cambios en política de inversión, áreas de negocio y líneas de productos | Download | |
22 Dec 2011 | Composición del Consejo de Administración | Download |